Cilostazol-d4

Cilostazol-d4 is intended for use as an internal standard for the quantification of cilostazol (Cay-15035) by GC- or LC-MS. Cilostazol is a phosphodiesterase 3A (PDE3A) inhibitor (IC50 = 0.2 µM for the platelet enzyme). It is selective for PDE3A over PDE1, -2, -4, and 5 (IC50s = >5 µM for all). Cilostazol inhibits collagen- or ADP-induced aggregation of isolated rabbit platelets (IC50s = 29 and 31 µM, respectively). In vivo, cilostazol (30 mg/kg) reduces thrombus formation by 84% in a mouse model of pulmonary thromboembolism. It reduces cardiac fibrosis and prevents the development of diastolic dysfunction and cardiac hypertrophy induced by a high-fat diet and angiotensin II in mice. Formulations containing cilostazol have been used in the treatment of the symptoms of intermittent claudication in peripheral vascular disease.Formal Name: 6-(4-(1-(cyclohexyl-2,2,6,6-d4)-1H-tetrazol-5-yl)butoxy)-3,4-dihydroquinolin-2(1H)-one. CAS Number: 1215541-47-1. Molecular Formula: C20H23D4N5O2. Formula Weight: 373.5. Purity: >99% deuterated forms (d1-d4). Formulation: (Request formulation change), A solid. Solubility: DMSO: Slightly soluble, Methanol: Slightly soluble. SMILES: O=C(N1)CCC2=C1C=CC(OCCCCC3=NN=NN3C4C([2H])([2H])CCCC4([2H])[2H])=C2. InChi Code: InChI=1S/C20H27N5O2/c26-20-12-9-15-14-17(10-11-18(15)21-20)27-13-5-4-8-19-22-23-24-25(19)16-6-2-1-3-7-16/h10-11,14,16H,1-9,12-13H2,(H,21,26)/i6D2,7D2. InChi Key: RRGUKTPIGVIEKM-KXGHAPEVSA-N.